Accurately detect stimulant use
Enhancing treatment outcomes through targeted screening
Stimulants, or sympathomimetic amines, increase central nervous system activity and can be used to treat and manage attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity. While some stimulants have pharmacological applications, others are categorized as Scheduled I compounds by the Drug Enforcement Agency and are often sold illicitly and abused. As a result, many professional practice guidelines recommend compliance testing in patients prescribed stimulant medications.
We now offer a targeted, high-resolution mass spectrometry screening panel that identifies and confirms the presence of 10 stimulants and phencyclidine (PCP) with a single test. Utilizing mass spectrometry in place of traditional, immunoassay testing not only increases specificity, but eliminates false positives caused by cross-reactivity with other medications. By reducing the need for additional confirmatory testing, the targeted stimulant screen saves time and money while enabling clinicians to accurately detect stimulant use and monitor compliance.
Targeted screening for enhanced detection
Ensure adherence to federal and state regulations by:
Substances assessed include, but are not limited to:
Comprehensive monitoring profiles
Profiles which include TSTIM
By the numbers
of adults use prescription stimulants in the United States annually. 1
people misused prescription stimulants in 2018. 2
reduction in substance misuse when combining clinical urine drug tests with other risk-mitigation strategies. 3
Analysis of urine drug testing results by our experts, who apply the most up-to-date scientific data, enables further transparency and clear answers that illuminate patients’ drug use.
Pharmacokinetics of CNS stimulants
Substances that can interfere with simple (immunoassay) CNS stimulants screening results